Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2025-03-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
商誉减值测试评估报告
Regulatory Filings
2025-03-27 Chinese
2024年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2024年度监事会工作报告" (2024 Supervisory Board Work Report) of 启迪药业集团股份公司. It details the supervisory board's activities during 2024, including meetings held, reports reviewed (such as the 2023 annual report, quarterly reports for 2024, internal control evaluation reports, and audit reports), and opinions on the company's operations, financial management, internal controls, and compliance. The document is a comprehensive report from the supervisory board on their oversight and findings for the year 2024. It is not merely an announcement or a brief summary but a detailed supervisory report. This type of document aligns with the category of Management Reports (MDA), which includes management's detailed explanation of financial results, business trends, and outlook. It is not an Annual Report (10-K) itself, nor an Audit Report (AR) standalone, but a supervisory board report commenting on these. The document length (2575 characters) is relatively short but contains substantive content and detailed supervisory opinions, not just a notice or announcement. Therefore, the best fit is Management Reports (MDA).
2025-03-27 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2024 年年度报告全文" which translates to the "2024 Annual Report Full Text" of 启迪药业集团股份公司. It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, shareholder information, and full financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial data, management commentary, and comprehensive disclosures consistent with an official annual report filing. Therefore, this document is classified as an Annual Report (10-K). FY 2024
2025-03-27 Chinese
2024年年度财务报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告及财务报表" (Audit Report and Financial Statements) for the fiscal year 2024, covering the period from January 1, 2024 to December 31, 2024. It includes detailed audit opinions, key audit matters, and comprehensive financial statements such as consolidated and parent company balance sheets, profit and loss statements, and cash flow statements. The presence of an audit opinion section, detailed financial data, and extensive notes indicates this is a standalone audit report rather than a full annual report or a brief announcement. The document length is substantial (15,000 characters), and it contains actual financial data and audit details, not just a certification or announcement. Therefore, it fits the category of Audit Report / Information (AR). FY 2024
2025-03-27 Chinese
2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as "启迪药业集团股份公司2024 年年度报告摘要" which translates to "2024 Annual Report Summary". It contains detailed financial data for the year 2024, including revenue, net profit, assets, and quarterly breakdowns. It also discusses company business, industry conditions, management strategies, and shareholder information. The document length is 7,881 characters, which is substantial and contains actual financial data and analysis, not just an announcement or a certification. The content aligns with the characteristics of an Annual Report (10-K) or its equivalent in the Chinese market. Since it is an annual report summary, it is still classified under Annual Report (10-K) as it provides comprehensive yearly financial and operational information. FY 2024
2025-03-27 Chinese
公司舆情应对工作制度
Governance Information Classification · 95% confidence The document is titled as a "舆情应对工作制度" which translates to "Public Opinion Response Work System" or "Crisis Management Policy" for the company. It outlines internal policies, organizational structure, responsibilities, principles, and procedures for managing public opinion and media crises. There is no financial data, no mention of financial results, no regulatory filings or announcements of voting results, no management changes, no earnings or capital updates, and no legal proceedings. The document is a governance-related internal policy document focused on communication and crisis management. It does not fit into financial reports or announcements but aligns with governance information about company internal rules and practices. The document length is 3267 characters, which is relatively short and detailed policy text, not an announcement or a brief summary. Therefore, the best fitting category is Governance Information (CGR).
2025-03-27 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.